Cyteir Therapeutics is a company that develops synthetic lethal therapies to treat cancer. It offers CYT-0851, an orally delivered investigational drug that is designed to inhibit the protein RAD51 to force tumor cells into a cell-death pathway. The company exploits the vulnerability of cancer cells to targeted treatments that disrupt DNA damage response and repair.